Latest Therapeutics News

Page 34 of 48
Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.
Ada Torres
Ada Torres
11 June 2025
EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.
Victor Sage
Victor Sage
11 June 2025
Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.
Ada Torres
Ada Torres
11 June 2025
Invion Limited has addressed ASX queries over the timing and content of its cleansing notice, confirming encouraging early results from its Phase I/II non-melanoma skin cancer trial using Photosoft™ technology.
Ada Torres
Ada Torres
11 June 2025
PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.
Ada Torres
Ada Torres
11 June 2025
Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.
Ada Torres
Ada Torres
11 June 2025
Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.
Ada Torres
Ada Torres
10 June 2025
Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.
Ada Torres
Ada Torres
10 June 2025
Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.
Ada Torres
Ada Torres
10 June 2025
Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.
Ada Torres
Ada Torres
10 June 2025
Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.
Ada Torres
Ada Torres
4 June 2025
Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.
Ada Torres
Ada Torres
4 June 2025